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Introduction: Irritable bowel syndrome (IBS) and fibromyalgia syndrome (FMS) are two common central
sensitization disorders frequently associated in the same patient, and some of these patients with IBS plus FMS
(IBS/FMS) could actually be undiagnosed of coeliac disease (CD). The present study was an active case finding for
CD in two IBS cohorts, one constituted by IBS/FMS subjects and the other by people with isolated IBS.
Methods: A total of 104 patients (89.4% females) fulfilling the 1990 ACR criteria for FMS and the Rome III criteria for
IBS classification and 125 unrelated age- and sex-matched IBS patients without FMS underwent the following
studies: haematological, coagulation and biochemistry tests, serological and genetic markers for CD (i.e., tissue
transglutaminase 2 (tTG-2) and major histocompatibility complex HLA-DQ2/HLA-DQ8), multiple gastric and
duodenal biopsies, FMS tender points (TPs), Fibromyalgia Impact Questionnaire (FIQ), Health Assessment Question-
naire (HAQ), 36-Item Short Form Health Survey (SF-36) and Visual Analogue Scales (VASs) for tiredness and gastro-
intestinal complaints.
Results: As a whole, IBS/FMS patients scored much worse in quality of life and VAS scores than those with isolated
IBS (P < 0.001). Seven subjects (6.7%) from the IBS/FMS group displayed HLA-DQ2/HLA-DQ8 positivity, high tTG-2
serum levels and duodenal villous atrophy, concordant with CD. Interestingly enough, these seven patients were
started on a gluten-free diet (GFD), showing a remarkable improvement in their digestive and systemic symptoms
on follow-up.
Conclusions: The findings of this screening indicate that a non-negligible percentage of IBS/FMS patients are CD
patients, whose symptoms can improve and in whom long-term CD-related complications might possibly be
prevented with a strict lifelong GFD.* Correspondence: lrodrigosaez@gmail.com
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Irritable bowel syndrome (IBS) is a common gastrointes-
tinal functional disease characterized by the presence of
chronic abdominal pain or discomfort associated with
changes in bowel habits, consisting predominantly of diar-
rhoea, constipation or alternating patterns; defecation ur-
gency; tenesmus; bloating; and abdominal distension [1,2].
Diagnosis of IBS is based on a positive history of gastro-
intestinal symptoms according to the Rome III criteria in
the absence of obvious alarm signs [3].
Several comorbidities which may occur more often
than expected by chance in IBS patients have been iden-
tified, including fibromyalgia syndrome (FMS), chronic
fatigue syndrome (CFS), gastro-oesophageal reflux dis-
ease, headache, backache, genitourinary symptoms, tem-
poromandibular joint disorder, anxiety and depression
[4,5]. Specifically, FMS, a prevalent, chronic, widespread
pain disorder affecting mainly females, classified according
to the 1990 American College of Rheumatology (ACR)
criteria [6], occurs in 20% to 32% of people with IBS,
and, in turn, 32% to 70% of people with FMS also
meet the criteria for IBS [7-9]. It has been reported
that the incidence of coeliac disease (CD) in patients
with IBS is much higher than that expected to be
found in the general population [10,11].
In spite of the fact that IBS, FMS and CD are three
prevalent disorders in Spain, no study has been carried
out to date to assess their association rate in this coun-
try. Therefore, with the aim of estimating the prevalence
of CD masquerading as IBS and/or FMS, a specific
protocol for active case-finding of CD was applied to
an IBS/FMS population from Asturias (Cantabrian coast,
northern Spain) and to a sex-, age- and size-matched
cohort of IBS patients without FMS to establish
comparisons.
Methods
During the 6-year period from 2007 through 2012, the
Rome III criteria for IBS diagnosis [3] and the 1990 ACR
criteria for FMS classification [6] were prospectively
applied to 442 consecutive patients upon their first visit
to an outpatient gastroenterology clinic at the Central
University Hospital of Asturias (HUCA; Oviedo, Spain).
Most patients were referred from the rheumatology and
internal medicine departments of the same hospital for
the study of a variety of long-standing gastrointestinal
symptoms.
Diagnosis of IBS was based on a positive history of ab-
dominal discomfort or pain associated with disturbed
defecation (according to the Rome III criteria) in the ab-
sence of obvious alarm features such as rectal bleeding,
iron deficiency anaemia, weight loss, fever, onset after
age 40 years, family history of colon cancer, nocturnal
symptoms and faecal soilage. When these symptoms arepresent, a more extensive evaluation must be carried out
in the differential diagnosis. The evaluation should in-
clude testing for coeliac sprue, structural colon lesions
such as polyps or cancer, parasites, endocrine disease,
bacterial overgrowth or carbohydrate malabsorption.
Despite the fact that IBS is no longer a diagnosis of
exclusion, since there is good evidence that a positive
clinical diagnosis is reliable enough [12], a battery of
tests was performed in all patients before they were en-
tered into the study, including a comprehensive medical
history, a thorough physical examination and complete la-
boratory haematological and biochemical broad screening.
In patients who did not respond to the usual therapies,
as well as in IBS cases in which other associated organic
illnesses, a specific hydogren breath test was performed
in order to exclude possible lactose intolerance or
small-bowel bacterial overgrowth. Appropriate faecal
cultures were done in some patients to exclude the pres-
ence of parasitic infections. Furthermore, in patients with
persistent diarrhoea, a total colonoscopy was performed
and random colonic biopsies were taken to rule out
microscopic colitis.
An immunological faecal occult blood test (iFOBT)
was done in patients over 50 years of age and in those
with a positive familial history of colon cancer in first-
degree relatives. If this iFOBT was positive, the study
was completed with a total colonoscopy.
The acceptance criteria for IBS patients included (1)
older than 18 and younger than 65 years of age, (2) meet-
ing the Rome III criteria, (3) absence of any other associ-
ated organic gastrointestinal disease and (4) not meeting
the 1990 ACR criteria for FMS. These selection criteria
were also used to select IBS patients with associated FMS,
except the last one, because by definition they had to fulfil
the 1990 ACR criteria for FMS classification. The exclu-
sion criteria were (1) incomplete or doubtful Rome III
criteria for IBS cases and incomplete or doubtful
1990 ACR criteria for IBS/FMS cases, (2) any abnor-
mal finding in the analytical screening or in the col-
onoscopy or colonic biopsies and (3) unwillingness to
participate in the study.
Only 263 (59%) of 442 individuals were eligible to par-
ticipate in the study, and 34 of the eligible people did not
agree to sign a written consent form, thus excluding them
from participation. Thus a total of 229 individuals agreed
to take part in this study. Participants were then assigned
to two groups: 104 comprising the IBS plus FMS group,
who fulfilled both the Rome III criteria for IBS diagnosis
and the 1990 ACR criteria for FMS classification, and 125
constituted the IBS group, who were unrelated age- and
sex-matched patients from the same Asturias population
who met the Rome III criteria for IBS diagnosis but did
not have FMS widespread pain or skin tender points (TPs)
and did not meet the 1990 ACR criteria.
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voluntary basis after signing a specific informed consent
form. The study was approved by the HUCA Research
and Ethics Committee according to the principles in-
cluded in the modified Declaration of Helsinki.
Outline of the study protocol
Initially, every selected participant underwent an up-
dated medical history, a quality of life (QoL) battery of
tests and a thorough physical examination.
Tender points
The FMS TPs were identified by digit pressure on the 18
locations recommended by the 1990 ACR criteria [6].
This test was routinely carried out in the clinical setting.
Digital palpation with the thumb pad was performed on
the standard TP sites on a copy of the body figure (front
and back) with location of all TPs that we found in each
patient included in the clinical record. An approximate
force of 4 kg, sufficient to blanch the nail bed of the
thumb, was applied over each of these TPs. The TPs
were palpated with constant palpation for about 4 sec-
onds. Patients responded ‘yes’ or ‘no’ if they had any
pain. When they responded ‘yes’, the examiner asked
them to rate their pain on a scale of 0 (no pain) to 10
(worst pain) and recorded each response on the body
figure.
Physical, mental, psychological, social functioning and
quality of life questionnaires
Each participant filled out the self-administered Spanish
version form of the Fibromyalgia Impact Questionnaire
(FIQ) [13], the Stanford Health Assessment Questionnaire
(HAQ) [14] and the 36-Item Short Form Health Survey
(SF-36) [15].
The FIQ is a 10-item instrument that measures, in a
range from 0 to 80 points, the physical functioning,
work status and degree of depression, anxiety, sleep,
pain, stiffness, fatigue and well-being, with scores of 0 to
39, 40 to 59 and 60 or greater evaluated as mild, moder-
ate and severe FMS, respectively.
The 20-item disability scale portion of the HAQ mea-
sures, in a range from 0 to 3 points, the patient’s diffi-
culty with activities of daily living and concomitant need
for help and assistive devices, with the highest scores
representing the maximum impairment (that is, 0 = able
to do without any difficulty, 1 = some difficulty, 2 =much
difficulty and 3 = unable to do).
The SF-36 is has two components: the Physical
Component Summary (PCS) and the Mental Component
Summary (MCS). Scores in the range from 0 to 100 punc-
tuate each of these aspects, with the lowest scores indicat-
ing the poorest health status. No cutoff values on the
SF-36 for classifying the impact of disease have beenestablished yet. For guidance, the reported values for
adults in the Spanish general population (expressed as
mean and standard deviation) [16] were PCS 73.0
(27.8) and MCS 74.4 (24.4).
Laboratory tests
Complete blood cell counts were performed with the
CELL-DYN 3500 automated haematology analyser
(Abbott Cientifica, Madrid, Spain). Coagulation panels
were carried out with the IL ACL 3000 Coagulation
Analyzer (Beckman Coulter, Brea, CA, USA). Analytical
biochemistry tests were performed on a Roche Hitachi au-
tomated modular chemistry analyser (Roche Diagnostic
Systems, Indianapolis, IN, USA) for SXA-phosphoprotein-
binding domains using enzymatic or kinetic methods,
including urea, glucose, total proteins, albumin, C-reactive
protein, calcium, folate, vitamin B12, creatinine, creatine
kinase, lipid profile, liver function tests (LFTs), iron me-
tabolism tests, immunoglobulin G (IgG), IgA and IgM,
rheumatoid factor, thyroid function test and urinalysis
with microscopic examination of sediment.
Antinuclear antibodies (ANAs) and antithyroid per-
oxidase (anti-TPO) antibodies were measured in each
participant, and in those individuals with altered LFTs
antimitochondrial antibodies (AMAs) were also assessed.
Determination of these biomarkers was performed by
indirect immunofluorescence assay on the HEp-20-10
cell line according to the manufacturer’s instructions
(EUROIMMUN, Lübeck, Germany). Anti-IgA tissue
transglutaminase subtype 2 (tTG-2) was measured by
using a commercially available enzyme-linked immuno-
sorbent assay kit (Phadia Diagnostics, Uppsala, Sweden).
To assess the participants’ genetic susceptibility to CD,
the major histocompatibility complex class II human
leucocyte antigen (HLA) marker HLA-DQ2 was charac-
terized by means of a polymerase chain reaction (PCR)
with a commercially available kit (PROTRANS HLA
Celiac Disease Domino System; PROTRANS, Hockenheim,
Germany). Characterization of the HLA-DQ8 haplotype
was not systematically assayed in this explorative study, but
it was carried out in isolated HLA-DQ2-negative cases
showing villous atrophy in duodenal biopsy.
Duodenal biopsy studies
An upper gastrointestinal endoscopy with at least four
duodenal biopsies was performed in all patients follow-
ing the usual methodology employed in our service for
CD diagnosis [17]. Samples were routinely stained with
haematoxylin and eosin (H & E) and with anti-CD3 im-
munohistochemical monoclonal antibodies to count the
number of intraepithelial lymphocytes (IELs) and in turn
to quantify them per 100 epithelial cells. Samples were
studied by two expert pathologists at HUCA and classi-
fied into the following types according to the histological
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modified by Oberhüber et al. [19]: stage 0: histological
normal duodenum; stage 1: increased IEL infiltration
with a total count of 25% or greater; stage 2: crypt
hyperplasia and diffuse chronic inflammatory infiltrate
at the lamina propria; and stage 3: villous atrophy, which
was subdivided into three categories: (a) mild, (b) mod-
erate and (c) severe.
Helicobacter pylori was systematically investigated by
taking endoscopic biopsies from the antrum (n = 2) and
the corpus of the stomach (n = 2). Antibiotics, proton
pump inhibitors (PPIs) and drugs containing bismuth
and H2 blockers were stopped within the previous
2 weeks. One antral biopsy was immediately used for a
quick urease test (Pronto Dry Kit; Pentland Medical Ltd,
Edinburgh, UK). The rest of the samples were used for
histopathological examination (that is, routine H & E
staining, Giemsa staining and immunohistochemistry
using polyclonal anti-H. pylori antibody) and microbial
cultures. Positive cases received triple therapy compris-
ing 14-day treatment with PPI (standard dose twice
daily), clarithromycin (500 mg twice daily) and amoxicil-
lin (1,000 mg twice daily). After treatment was com-
pleted, H. pylori eradication was confirmed 4 to 6 weeks
later with a rapid urease breath test [20,21].Statistical analysis
Descriptive statistics (means calculations, standard devia-
tions and observed ranges) were used on continuous pa-
rameters. For qualitative variables, percentages were used.
Kruskal–Wallis analysis of variance (ANOVA) contin-
gency tables were analysed. If the continuous variables
followed a normal distribution, Student’s t-test was used.
Differences between groups were evaluated by ANOVA
followed by post hoc analysis using Fisher’s test. The statis-
tical calculations were performed using SPSS 15.0 soft-
ware (SPSS Inc, Chicago, IL, USA), and P values less than
0.05 were considered significant.Results
Demographics
The 229 participants in the study were unrelated Cauca-
sians from the Principality of Asturias, Spain. No statis-
tical differences among groups were found regarding
age, gender, marital status, labour status or educational
level. Participants included in the IBS/FMS Marsh stage
1 group had a slightly higher body mass index indicative
of moderate overweight. Ten patients from the FMS/IBS
group classified as Marsh stage 1 and two classified as
Marsh stage 3 had a total of 12 first-degree relatives
(that is, 3 parents, 6 siblings and 3 offspring) previously
diagnosed with CD. Five patients from the FMS/IBS
group and four from the IBS group declared that theyhad five and four siblings, respectively, diagnosed by
other physicians as FMS patients (Table 1).Duodenal biopsy histological findings and serological and
genetic markers of coeliac disease
IEL counts were significantly higher in the IBS/FMS
group than in the IBS group (odds ratio (OR) = 2.577; 95%
confidence interval (CI) = 1.283 to 5.154). The prevalence
of Marsh stage 1 cases was higher in the IBS/FMS co-
hort, and seven cases showed villous atrophy (classified as
Marsh stage 3) compared with none in the IBS group,
with clear differences observed between both groups
(OR = 8.750; 95% CI = 4.699 to 16.289).
About half of the patients in both groups were infected
with H. pylori (42% in the IBS/FMS group and 46% in
the isolated IBS group) and treated with 14-day triple
therapy. H. pylori eradication was confirmed in 90% of
IBS/FM cases and in 88% of isolated IBS cases by the
urease breath test, without any differences in prevalence
and eradication percentages observed between them. Fifty
percent of FMS/IBS patients vs. twenty-four percent from
the IBS group were HLA-DQ2-positive, with a rising gradi-
ent of positivity proportional to the degree of histological
damage, that is, Marsh stage 0 (38%) <Marsh stage 1 (53%)
<Marsh stage 3 (86%). A HLA-DQ2-negative case with
lymphocytic infiltration and villous atrophy in the duodenal
mucosa was found to be HLA-DQ8-positive. High values
of IgA anti tTG-2 titres were found only in the seven IBS/
FMS cases classified as Marsh stage 3 (Tables 2 and 3).
Gastrointestinal symptoms
All patients complained of a combination of at least two
of the following gastrointestinal symptoms: abdominal
pain or discomfort, bloating, heartburn, constipation, diar-
rhoea and alternating diarrhoea and constipation. The
duration of symptoms was long-lasting in both groups,
without statistical differences between them (Table 4).
Fibromyalgia symptoms
IBS/FMS patients had a number of classical FMS symp-
toms, starting in most patients during their mid-40s.
Except for headaches, which were more frequent in
the Marsh stages 1 and 3 subgroups, the symptoms
appeared to be homogeneously distributed among the
Marsh stage subgroups (Table 4).
Tender points and quality of life questionnaires
IBS/FMS patients scored very high in TPs and on the FIQ
and HAQ scales and, conversely, very low on the SF-36
items. As a whole, these patients were classified as having
severe FMS. Patients with only IBS displayed significantly
better scores than the IBS/FMS patients on the SF-36 and
the VAS digestive and fatigue scales (Table 4).
Table 2 Gastroduodenal histological findings and genetic
and serological markersa
Cohorts IBS
(N = 125)
IBS/FMS
(N = 104)
P value
Gastroduodenal biopsy
IEL count per 100 epithelial cells 15 (10) 27 (26) <0.001
Marsh stage 0 105 (84) 39 (37) <0.001
Marsh stage 1 20 (16) 58 (56) <0.001
Marsh stage 3 2 (2) 7 (7) <0.001
Helicobacter pylori (+) 58 (46) 44 (42) 0.080
CD laboratory biomarkers
HLA-DQ2 A1/B1 (+) 30 (24) 52 (50) <0.001
IgA anti-tTG-2 serum levels, U/ml 0.4 (0.1) 4.7 (20) <0.001
aCD, coeliac disease; HLA, major histocompatibility complex class II human
leucocyte antigen; IBS, irritable bowel syndrome; IBS/FMS, irritable bowel
syndrome plus fibromyalgia syndrome; IEL, intraepithelial lymphocyte count
per 100 epithelial cells in duodenal biopsy sample; IgA, immunoglobulin A;
tTG, tissue transglutaminase. Data are expressed as total and percentage of
the total value or as mean and standard deviation.
Table 1 Demographic dataa
IBS/FMS cases
P value Classified by Marsh stage P value
IBS IBS/FMS (IBS vs. FMS) Marsh stage 0 Marsh stage 1 Marsh stage 3 (Marsh stages 1 and
3 vs. Marsh stage 0)
Sample size 125 104 NA 39 58 7 <0.001
Females 104 (84) 93 (89) 0.122 34 (87) 52 (90) 7 (100) 0.595
Age, years 51 (8) 50 (8) 0.668 49 (7) 51 (9) 49 (12) 0.146
BMI, kg/m2 27 (4) 26 (4) 0.388 25 (3) 28 (5) 24 (3) 0.003
Marital status
Single 3 (2) 2 (2) 0.748 1 (3) 2 (3) 1 (14) 0.892
Married 103 (82) 92 (89) 0.272 33 (85) 52 (90) 4 (57) 1.000
Domestic partnership 10 (8) 5 (5) 0.481 4 (10) 1 (0) 1 (14) 0.123
Separated/divorced 10 (8) 5 (5) 0.481 1 (3) 3 (5) 1 (14) 0.722
Education level
None 2 (2) 2 (2) 0.748 2 (5) 2 (3) 1 (14) 0.834
Primary school 92 (73) 75 (72) 0.918 29 (74) 42 (72) 2 (28) 0.865
Secondary education 27 (22) 24 (23) 0.914 10 (26) 11 (19) 3 (42) 0.810
Higher education 4 (3) 3 (3) 0.804 3 (8) 3 (5) 1 (14) 0.449
Labour status
Employed 59 (47) 47 (45) 0.864 21 (54) 24 (41) 2 (29) 0.242
Unemployed 26 (21) 22 (21) 0.922 7 (18) 13 (22) 2 (29) 0.844
Householder chores 23 (18) 19 (18) 0.883 8 (20) 9 (15) 2 (29) 0.709
Retired/pensioner 17 (14) 16 (15) 0.846 3 (8) 12 (21) 1 (14) 0.160
Participants with relatives diagnosed
with CD
– 12 (11) NA 2 (5) 10 (17) 2 (29) 0.161
Participants with relatives diagnosed
with FMS
4 (3) 5 (5) 0.389 1 (2) 4 (7) 1 (14) 0.619
aBMI, body mass index; CD, coeliac disease; FMS, fibromyalgia syndrome; IBS, irritable bowel syndrome; NA, not applicable. Data are expressed as total and
percentage of the total value or mean and standard deviation.
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Practically all patients received prescriptions for anti-
spasmodic, antidiarrhoeal or laxative medications. The
use of anxiolytic and antidepressant medications was
substantial in both groups, reflecting the high prevalence
of anxiety and depression in these patients. The use of
analgesics, antidepressants, benzodiazepines, hypnotics,
pregabalin, laxatives and opiate patches, as well as the
number of drugs prescribed per patient per day, were
significantly higher in the IBS/FMS group than in pa-
tients with only IBS, specifically in the Marsh stages 1
and 3 subgroups (Table 5).Haematological, biochemical and immunological
laboratory tests
Overall, mean values for the different general haem-
atological and biochemical analyses were normal or
slightly altered, with a wide dispersion and broad range
(Table 6).
Table 3 Laboratory results in inflammatory bowel syndrome and fibromyalgia syndrome subgroupsa
Laboratory test IBS IBS/FMS cases classified by Marsh stage P value
(N = 125) (N = 104) (Marsh stages 1 and
3 vs. Marsh stage 0)Normal mucosa Lymphocytic enteritis Villous atrophy
Marsh stage 0
(n = 39)
Marsh stage 1
(n = 58)
Marsh stage 3
(n = 7)
IEL count per 100 epithelial cells 15 (10) 14 (2) 35 (5) 37 (5) <0.001
Helicobacter pylori (+) 58 (46) 17 (43) 24 (41) 3 (43) 0.159
HLA-DQ2 A1/B1 (+) 30 (24) 15 (38) 31 (53) 6 (86) 0.052
IgA anti tTG-2, U/ml 0.4 (0.1) 0.5 (0.1) 0.9 (0.7) 60.4 (52) 0.001
aHLA, major histocompatibility complex class II human leucocyte antigen; IBS, irritable bowel syndrome; IBS/FMS, irritable bowel syndrome plus fibromyalgia
syndrome; IEL, intraepithelial lymphocyte count per 100 epithelial cells in duodenal biopsy sample; IgA, immunoglobulin A; tTG, tissue transglutaminase. Data are
expressed as mean and standard deviation or total and percentage of the total value.
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in 29 IBS/FMS cases, most of which were classified as
Marsh stages 1 and 3, compared with 4 ANA-positive
patients with IBS alone (P < 0.001). However, none of
the ANA-positive patients met the 1982 ACR criteria
necessary for the diagnosis of systemic lupus erythema-
tous (SLE) [22].
High serum levels of anti-TPO antibodies were found
in ten Marsh stage 1 cases and two Marsh stage 3 cases
in the IBS/FMS group. Nevertheless, only five of these
positive cases showed minor, transitory thyroid function
test alterations, compatible with hypothyroidism in four
cases and with hyperthyroidism in one case, but none
of these showed clinical manifestations of thyroid
dysfunction.
AMAs were positive in five IBS/FMS cases (four were
Marsh stage 1 and one was Marsh stage 3). Each of these
patients presented with mild elevation of serum aspar-
tate aminotransferase, alanine aminotransferase, alka-
line phosphatase and γ-glutamyl transpeptidase levels,
but without clinical manifestations of liver disease,
and thus were diagnosed as having subclinical auto-
immune hepatitis.
Discussion
The most remarkable finding of this pilot study was our
finding of seven cases with solid histological, laboratory
and clinical evidence of CD in a group of FMS patients
(mostly females) whose clinical symptoms started with
gastrointestinal relapsing disorders mimicking IBS when
they were in their 20s. They developed multisystem
complaints about two decades later, with very negative
effects in their health-related QoL. Remarkably, almost
30% of these CD-associated IBS and FMS patients had a
family history of CD, and a significant number of them
also had high serum titres of ANAs, anti-TPOs and
AMAs. Interestingly enough, these seven patients were
started on a gluten-free diet (GFD), which led to signifi-
cant improvement in their digestive and systemic symp-
toms upon follow-up examinations.A recent systematic review concluded that biopsy-
proved CD in cases meeting the diagnostic criteria for
IBS was more than fourfold higher than that in controls
without IBS [23]. Although further work is needed to
definitively confirm that CD is a significant problem in
terms of misdiagnosis in IBS, it has been estimated that
testing IBS patients for CD can be cost-effective in clin-
ical practice [24].
In recent years, a possible causal link between IBS,
FMS and multisymptom forms of adult CD has been
suspected on the basis of some cases with overlapping
symptoms involving gastrointestinal, musculoskeletal and
other body systems that have had similar clinical features
[25,26]. In addition, a few case reports describing isolated
patients with FMS and CD simultaneously, all of whose
symptoms dramatically resolved after the removal of glu-
ten from their diet, have been reported [27,28].
Studies of the prevalence of CD in European patients
with IBS are scant. Nevertheless, two separate prospective
studies carried out in Sheffield, UK [29], and in Krakow,
Poland [30], respectively, concluded that IBS patients were
seven times more likely than matched controls to have
biopsy-proven CD.
As previously stated, it is widely accepted that IBS and
FMS are interrelated diseases, with IBS occurring in
about 50% of FMS patients [4,7]. It is also well-known
that the association of CD with IBS is not infrequent, be-
cause the prevalence of CD in IBS is four- to sevenfold
higher than the prevalence of CD alone expected to be
found in the general population [23,29,30].
CD is a multisystem autoimmune disorder related to a
permanent intolerance of gluten stored in wheat, rye,
barley and other cereals. It affects 1% to 2% of individ-
uals (mainly females) worldwide. CD patients generally
are carriers of one of the two major histocompatibility
complex class II HLA genotypes, HLA-DQ2 or HLA-
DQ8. In these patients, gliadin peptides trigger an aber-
rant immune response that results in the production of
tTG autoantibodies and an immune-mediated chronic
inflammation of the small-bowel mucosa. This immune-
Table 4 Main symptoms, associated diseases, tender points and test scoresa
Symptoms and diseases IBS IBS/FMS P value IBS/FMS cases classified by Marsh stage P value
(N = 125) (N = 104) (IBS vs. FMS) Marsh stage 0
(N = 39)
Marsh stage 1
(N = 58)
Marsh stage 3
(N = 7)
(Marsh stages 1 and
3 vs. Marsh stage 0)
Widespread pain – 104 (100) NA 39 (100) 58 (100) 7 (100) 1.000
Digestive complaints 125 (100) 104 (100) 1.000 39 (100) 58 (100) 7 (100) 1.000
Fatigue 31 (25) 94 (90) <0.001 35 (90) 53 (91) 6 (86) 0.878
Sleep disturbances 28 (22) 87 (84) <0.001 29 (74) 52 (89) 6 (86) 0.134
Anxiety/depression 77 (62) 69 (66) 0.273 22 (56) 42 (72) 5 (71) 0.251
Skin problemsb 31 (25) 52 (50) <0.001 20 (51) 28 (48) 4 (57) 0.888
Cognitive dysfunction 5 (4) 37 (36) <0.001 14 (36) 20 (34) 3 (43) 0.908
Urinary urgency 6 (5) 30 (29) <0.001 10 (26) 18 (31) 2 (29) 0.848
Headachesc 24 (19) 29 (28) 0.082 5 (13) 21 (36) 3 (43) 0.028
Balance problems/dizziness 9 (7) 29 (28) <0.001 10 (26) 17 (29) 2 (29) 0.924
Joint stiffness 2 (2) 27 (26) <0.001 9 (23) 16 (28) 2 (29) 0.872
Paraesthesias 4 (3) 25 (24) <0.001 9 (23) 14 (24) 2 (29) 0.952
Osteoporosis 7 (6) 14 (13) 0.034 2 (5) 10 (17) 2 (29) 0.110
TMJ disorder – 13 (12) NA 5 (13) 6 (10) 2 (29) 0.520
Restless legs syndrome – 13 (12) NA 3 (8) 8 (14) 1 (14) 0.277
Sjögren syndrome – 8 (8) NA – 7 (12) 1 (14) NA
Raynaud syndrome 1 (1) 5 (5) 0.069 – 5 (9) 1 (14) NA
Tender points (scale 0 to 18) – 16.1 (1.9) NA 14.8 (1.2) 16.9 (1.8) 16.3 (2.4) <0.001
FIQ score (scale 0 to 80) – 68 (9) NA 63 (7) 70 (9) 74 (3) <0.001
HAQ score (scale 0 to 3) – 1.5 (0.6) NA 1.4 (0.5) 1.6 (0.6) 1.7 (0.6) 0.298
SF-36 Physical Component
(scale 0 to 100)
44 (13) 29 (5) <0.001 30 (7) 29 (1) 27 (4) 0.380
SF-36 Mental Component
(scale 0 to 100)
41 (13) 29 (14) <0.001 35 (10) 25 (13) 17 (4) <0.001
VAS fatigue score (scale 0 to 10) 3 (1) 7 (2) <0.001 7 (0.8) 8 (1.5) 8 (0.3) 0.006
VAS digestive score (scale 0 to 100) 31 (12) 47 (8) <0.001 46 (9) 47 (9) 48 (2) 0.516
Gastrointestinal symptoms
duration, years
29 (5) 29 (7) 0.917 29 (5) 29 (8) 28 (9) 0.905
Extraintestinal systemic symptom
duration, years
– 9 (2) NA 9 (2) 9 (2) 7 (4) 0.813
aFIQ, Fibromyalgia Impact Questionnaire; HAQ, Health Assessment Questionnaire; IBS, inflammatory bowel syndrome; IBS/FMS, inflammatory bowel syndrome/
fibromyalgia syndrome; NA, not applicable; SF-36, 36-Item Short Form Health Survey; TMJ = temporomandibular joint; VAS, Visual Analogue Scale. bSkin problems
included itchy, dry or burning skin; chronic urticaria; and one case of dermatitis herpetiformis that was classified as Marsh stage 3. cHeadaches included migraine,
tension and mixed headache syndrome. Data are expressed as total and percentage of total values or mean and standard deviation.
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intraepithelial lymphocytosis and crypt hyperplasia. CD
clinical manifestations may appear at any age together
with gastrointestinal and/or extraintestinal systemic
symptoms, although some diagnoses can be made in
asymptomatic individuals. Notably, adhering to a GFD
results in complete clinical remission and full intestinal
mucosa recovery in the vast majority of CD patients
[31,32].
The available level of scientific evidence supporting
the association of CD with FMS is mostly limited to a
low-powered, cross-sectional study in which a 2% inci-
dence of CD was detected among 50 Americanadolescents with FMS [27], an American nationwide sur-
vey reported that FMS was the physician’s initial diagno-
sis in 9% of 134 patients later diagnosed with CD [25].
Two case reports in the literature have described, re-
spectively, a child [27] and three women [28] with co-
morbid FMS and CD, all of whose symptoms resolved
very well once gluten was removed from their diet. In
the present study, we found that 6.7% patients with the
triad of IBS, FMS and CD showed remarkable symptom
improvement when placed on a GFD.
FMS is a complex chronic pain syndrome affecting 1%
to 3% of people worldwide. FMS often clusters in fam-
ilies and affects mainly females (85% or more) between
Table 5 Most frequently prescribed drugsa
Prescribed drugs IBS IBS/FMS P value IBS/FMS cases classified by Marsh stage P value
(N = 125) (N = 104) (BIS vs. FMS) Marsh stage 0
(N = 39)
Marsh stage 1
(N = 58)
Marsh stage 3
(N = 7)
(Marsh stages 1 and
3 vs. Marsh stage 0)
Analgesicsb 22 (18) 85 (82) <0.001 34 (87) 45 (78) 6 (86) 0.468
Omeprazole 102 (82) 82 (79) 0.360 29 (74) 47 (81) 6 (86) 0.659
Antidepressantsc 30 (24) 70 (67) <0.001 25 (64) 40 (69) 5 (71) 0.857
Pregabalin 4 (3) 60 (58) <0.001 19 (49) 36 (62) 5 (71) 0.319
Benzodiazepines/hypnotics 55 (44) 59 (57) 0.037 20 (51) 35 (60) 4 (57) 0.677
Antispasmodics/antidiarrhoealsd 58 (46) 52 (50) 0.341 17 (38) 33 (57) 2 (29) 0.220
Laxatives 14 (11) 42 (40) <0.001 10 (26) 27 (47) 5 (71) 0.027
Opiate patches – 17 (16) NA 1 (2) 12 (21) 4 (57) <0.001
Number of drugs prescribed
per patient per day
1.8 (1.1) 4.6 (2.2) <0.001 3.9 (1.9) 4.9 (2.2) 6.6 (1.5) 0.003
aIBS, inflammatory bowel syndrome; IBS/FMS, inflammatory bowel syndrome/fibromyalgia syndrome; NA = not applicable. bAnalgesics were usually used on an
irregular basis (on demand) and were generally nonsteroidal anti-inflammatory drugs, acetaminophen, tramadol, metamizole and codeine. cAntidepressants
prescribed were tricyclic antidepressants, selective serotonin reuptake inhibitors or other antidepressants. dAntispasmodics prescribed were mebeverine and/or
octylonium bromide, and antidiarrhoeal medications prescribed were loperamide and diphenoxylate/atropine. Data are expressed as total value and percentage
of the total value or mean and standard deviation.
Rodrigo et al. Arthritis Research & Therapy 2013, 15:R201 Page 8 of 12
http://arthritis-research.com/content/15/6/R201their 20s and 50s, although the incidence rises with age,
reaching 7% in women over 70 years of age. Clinically,
FMS is characterized by widespread soft-tissue pain;
generalized TPs; abnormal fatigue; sleep disturbance;
and skin, gastrointestinal, urinary, cognitive and various
other symptoms. FMS symptoms vary from person to
person in both number and severity and tend to fluctu-
ate in response to emotional or physical stress, lack of
sleep, exertion, injuries, infections, menstruation and
weather changes, among other stressors. Because no ef-
fective treatment for FMS control is currently available,
its personal, familial, labour-related and social impacts
are very negative, usually leading to excessive use of
healthcare services [6,33,34]. The pathogenesis of FMS
remains elusive, although it is believed that genetic, im-
munologic and environmental factors contribute to its
complex, multifactorial pathological process, and it is ac-
cepted that a combination of increased peripheral im-
pulse input and increased central pain sensitivity, with
aberrant pain facilitation and impaired inhibition, may
be responsible for this disorder. The relative role of per-
ipheral and central factors and ascending and descend-
ing pathways are not known, but probably all of the
neural pathways, in variable proportions and depending
of each case, may be involved in an interactive way
[35,36]. No laboratory or imaging techniques for an ac-
curate diagnosis of FM are currently available, thus ne-
cessitating an exclusion-based differential diagnosis to
rule out other, similarly typified diseases after appropri-
ate evaluation screening in patients fulfilling the 1990
ACR criteria for FMS [6]. Interestingly, FMS is fre-
quently associated with other rheumatic disorders, infec-
tions and systemic illnesses. For example, 30% of
females with ankylosing spondylitis, 16% with SLE, 15%with rheumatoid arthritis, 24% with psoriatic arthritis,
11% with osteoarthritis, 9.2% with Behçet’s disease and
up to 40% with joint hypermobility syndrome meet
the ACR criteria for FMS. FMS has also been docu-
mented in women with hyperprolactinaemia (71%),
hypothyroidism (34%), Crohn’s disease (26%), ulcerative
colitis (11%), diabetes mellitus (17%) and endometriosis
(6%). An increased prevalence of FMS has also been re-
ported in patients with hepatitis C virus (57%) and HIV
(29%), as well as following physical trauma in 22% of pa-
tients, mostly women, with neck injuries and in 1.7% pa-
tients with lower-extremity fractures [33,34,36,37]. FMS
is frequently found to be associated with other central
sensitivity syndromes, such as: post-traumatic stress dis-
order (57%), CFS (55%), multiple chemical sensitivities
(55%), IBS (41%), tension, migraine and mixed head-
aches (26%), TMJ disorder (24%), bulbar vestibulitis syn-
drome (23%), Gulf War syndrome (18%) and interstitial
cystitis (15%) [33,36].
A separate issue is the importance of the significant
number of IBS/FMS patients with related CD in our
series who exhibited an excessive prevalence of ANA,
anti-TPO and AMA autoantibodies. Indeed, there are
two populations included in the present study: one con-
stituted 104 IBS/FMS patients and the other 125 pa-
tients with only IBS. The IBS/FMS group had more
frequent positive ANAs than those with only IBS (28%
vs. 3%; P < 0.001), and the same was true for anti-TPO
antibodies (11% vs. 0%), AMAs (5% vs. 0%) and anti-tTG
autoantibodies (mean serum levels = 0.4 vs. 4.7; P < 0.001).
However, none of the ANA-positive participants met the
1982 ACR criteria necessary for the diagnosis of SLE,
none with increased anti-TPO antibodies showed clinical
manifestations of thyroid dysfunction and none of the
Table 6 Haematological and biochemical laboratory findingsa
Laboratory panels IBS IBS/FMS P value IBS/FMS cases classified by Marsh stage P value
(N = 125) (N = 104) (IBS vs. FMS) Marsh stage 0
(N = 39)
Marsh stage 1
(N = 58)
Marsh stage 3
(N = 7)
(Marsh stages 1 and
3 vs. Marsh stage 0)
Haemoglobin, g/dl 13 ( 1) 13 (1) 1.000 13 (1) 14 (1) 13 (1) 0.271
WBC count, n × 103 7.6 (1) 7.0 (2) 0.002 7.6 (1) 6.7 (2) 5.8 (2) 0.002
Platelet count, n × 103 272 (37) 257 (54) 0.021 274 (37) 248 (60) 232 (57) 0.010
Prothrombin activity (%) 98 (5) 98 (9) 0.777 98.2 (8) 98 (10) 98 (4) 0.741
aPTT, seconds 34 (2) 35 (2) 0.024 35 (2) 33 (2) 33 (1) 0.019
Fibrinogen, mg/dl 261 (111) 349 (152) <0.001 259 (113) 385 (128) 552 (218) <0.001
Glucose, mg/dl 108 (27) 101 (20) 0.018 109 (27) 96 (13) 99 (9) 0.020
Urea, mg/dl 44 (23) 40 (14) 0.022 43 (21) 38 (7) 38 (8) 0.017
CK, IU/L 59 (7) 60 (9) 0.985 58 (7) 61 (10) 62 (12) 0.276
CRP, mg/L 0.6 (0.6) 0.5 (0.6) 0.211 0.6 (0.7) 0.5 (0.7) 0.3 (0.2) 0.466
IgG, g/L 9.7 (0.5) 9.9 (1.0) 0.098 9.6 (0.5) 10.2 (1.2) 9.6 (1.0) 0.107
IgA, g/L 2.4 (0.5) 2.6 (0.6) 0.126 2.4 (0.6) 2.7 (0.6) 2.4 (0.5) 0.008
IgM, g/L 1.8 (0.4) 1.9 (0.5 ) 0.126 1.9 (0.3) 1.9 (0.6) 1.6 (0.5) 0.722
Iron, μg/ml 68 (19) 80 (29) 0.001 66 (20) 89 (32) 91 (21) <0.001
Ferritin, ng/ml 56 (23) 88 (164) 0.821 48 (28) 114 (214) 90 (70) 0.064
TSI, μg/dl 20 (11) 24 (9) 0.001 20 (11) 25 (8) 25 (6) 0.001
Cholesterol, g/dl 176 (24) 174 (39) 0.293 192 (18) 166 (42) 144 (52) 0.001
AST, IU/L 20 (9) 23 (9) <0.001 21 (5) 25 (11) 30 (20) 0.269
ALT, IU/L 21 (6) 25 (13) 0.803 21 (7) 27 (17) 19 (10) 0.765
GGT, IU/L 23 (20) 28 (23) 0.074 24 (20) 31 (22) 23 (33) 0.060
ALP, IU/L 70 (23) 76 (26) 0.012 74 (30) 78 (23) 77 (22) 0.066
Bilirubin, mg/dl 0.7 (0.2) 0.8 (0.2) 0.639 0.7 (0.1) 0.7 (0.2) 0.9 (0.24) 0.591
TSH, μU/ml 1.8 (0.6) 3.1 (5.9) 0.209 1.9 (0.7) 4.1 (7.8) 1.2 (0.8) 0.157
Folate, ng/dl 10 (4) 9 (3) 0.019 10 (3) 8 (3) 10 (5) 0.019
Vitamin B12, pg/ml 451 (168) 521 (206) 0.002 450 (170) 555 (213) 636 (238) 0.001
RF, IU/ml 13 (1) 13 (2) 0.858 13 (1) 13 (2) 14 (2) 0.775
ANAs (+) 4 (3) 29 (28) <0.001 3 (8) 23 (40) 3 (43) 0.002
Titres
1:160 4 (3) 23 (22) <0.001 4 (10) 18 (31) 1 (14) 0.004
1:320 – 3 (3) NA – 2 (3) 1 (14) NA
1:640 – 3 (3) NA – 2 (3) 1 (14) NA
Staining pattern
Speckled 4 (3) 25 (24) <0.001 4 (10) 21 (34) – NA
Homogeneous – 2 (2) NA – 1 (2) 1 (14) NA
Nucleolar – 2 (2) NA – – 2 (29) NA
Anti-TPO (+) – 12 (11) NA – 10 (17) 2 (29) 0.011
Serum levels, IU/ml – 31 (108) NA – 51 (140) 40 (72) NA
AMAs (+) – 5 (4) NA – 4 (7) 1 (0) NA
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Table 6 Haematological and biochemical laboratory findingsa (Continued)
Titres
1:160 – 1 (1) NA – 1 (2) – NA
1:320 – 2 (2) NA – 1 (3) 1 (14) NA
1:640 – 2 (2) NA – 2 (3) – NA
aALP, alkaline phosphatase; ALT, alanine aminotransferase; AMA, antimitochondrial antibody; ANA, antinuclear antibody; Anti-TPO, antithyroid peroxidase antibody;
aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; CK, creatine kinase; CRP, C-reactive protein; GGT, γ-glutamyl transpeptidase;
Ig, immunoglobulin; NA, not applicable; RF, rheumatoid factor; TSH, thyroid-stimulating hormone; TSI, Transferrin Saturation Index; WBC, white blood cell.
Values are expressed as mean and standard deviation or total value and percentage.
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liver disease.
Because FMS cannot be considered an autoimmune
disease, despite the fact that it is common in patients
with autoimmune disease and may be the source of
many of the symptoms and much of the disability in
these patients [38], the findings of our study are more
concordant with CD, an autoimmune disease often asso-
ciated with a variety of autoimmune diseases, including
type 1 diabetes mellitus, autoimmune thyroid disease,
autoimmune adrenal disease, Sjögren syndrome, rheuma-
toid arthritis, SLE, primary biliary cirrhosis, primary scler-
osing cholangitis, autoimmune cholangitis, autoimmune
hepatitis and IBS [32].
A secondary finding worthy of comment is the large
number of patients (20 in the IBS-only group and 58 in
the IBS/FMS group) with increased infiltration of IELs
(above 25% of enterocytes) with normal villous architec-
ture in the duodenal mucosa, a pathologic finding
known as lymphocytic duodenosis (LD). This condition,
also named lymphocytic duodenitis, nonatrophic lympho-
cytic enteritis or (in the gluten-sensitivity context) Marsh
stage 1, is an unspecific diagnosis of gluten intolerance
by itself. Therefore, such patients should not be diag-
nosed with CD solely on the basis of histological studies.
A recent prospectively designed study demonstrated that
only 16% of patients with LD will develop CD and that
the IEL count even becomes normal on repeated biop-
sies in up to 76% of patients [39]. In addition, different
studies have reported a variety of LD and non-gluten-
related sensitivity associations, such as drug intake (for ex-
ample, nonsteroidal anti-inflammatory drugs (NSAIDs)),
nongluten food protein intolerance (for example, cow’s
milk, eggs, peanuts and soy), autoimmune disorders (for
example, thyroiditis, type 1 diabetes mellitus, rheumatoid
arthritis, psoriasis, multiple sclerosis and SLE), several
inflammatory and/or infectious digestive disorders (for
example, Crohn’s disease, H. pylori, bacterial overgrowth,
tropical sprue, Giardia lamblia, Cryptosporidium and viral
infections), IgA deficiency and T-cell intestinal lymph-
oma [40,41].
About 80% of the IBS/FMS patients in our series were
taking NSAIDs on an irregular basis, and more than
40% from both cohorts were infected with H. pylori atthe beginning of the study. Therefore, it appears reason-
able to attribute the high prevalence of NSAID chronic
intake and H. pylori infection found in our series to
these two known confounder causes of LD. However, it
should be taken into account that ten (17%) of these
IBS-LD/FMS patients who tested positive for HLA-DQ2
A1/B1 and were also reported to have first-degree rela-
tives with CD, which are two laboratory and clinical fea-
tures compatible with a CD diagnosis.
The comorbid triad of IBS, chronic fatigue and muscu-
loskeletal pain is striking [26], and the fact that our pa-
tients reported a long history of digestive complaints
before the appearance of generalized soft-tissue pain,
multiple TPs, weakness and other multisystemic symp-
toms resembling FMS is concordant with the increased
prevalence of FMS reported by other series of women
with different chronic processes within the gastrointes-
tinal tract, such as IBS, Crohn’s disease and ulcerative
colitis [33,36] and makes it feasible to hypothesize that a
gluten-related autoimmune inflammatory process initi-
ated within the gastrointestinal tract may contribute, in
some gluten-sensitive patients with CD, to the well-
documented central nervous system sensitivity (with ab-
errant pain facilitation and descending inhibitory pain
impairment) responsible for FMS.
Despite the fact that our study included a relatively
small number of nonrandomized patients comprising
individuals referred to a gastroenterological clinic for
symptoms indicative of a risk for CD, making it difficult
to draw unequivocal conclusions, it appears evident that
our findings may provide insightful contributions into
the complex clinical picture of IBS/FMS CD-associated
disorder, adding new clinical evidence in favour of the
presence of a possible relationship between CD (and glu-
ten sensitivity in general), IBS and some cases of FMS.
Unfortunately, there are not any other available pub-
lished case-finding studies of adult patients with FMS to
establish comparisons.
Conclusion
The findings of this case-finding study indicate that
some misdiagnosed IBS/FMS patients could have under-
lying CD, which could contribute to IBS/FMS symptom
development and maintenance. If they were replicated in
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could have pivotal therapeutic connotations, because
one of the most disappointing aspects of FMS therapy is
that only a small number of patients experience substan-
tial relief when treated with the available US Food and
Drug Administration–approved medications (that is,
pregabalin, duloxetine and milnacipran), but a great
number of patients discontinue their treatment because
of drug-related adverse effects or its low effectiveness
[42-45].
The detection of CD-IBS/FMS-like index cases implies
that decisive therapeutic and preventative actions be
taken for these patients and their relatives with silent or
symptomatic, but not yet diagnosed, CD. These mea-
sures would include the implementation of a GFD,
which can potentially improve symptoms, reverse the in-
testinal mucosal pathological changes and prevent long-
term CD-related complications [31,32]. In addition, it is
important to provide genetic counselling to patients and
their families to help them understand the medical, psy-
chological and familial implications of this disease; edu-
cate them about management, inheritance, prevention,
testing and identification of reliable sources of informa-
tion and products; and support adherence to a lifelong
GFD regimen [46].
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